Louise Chen
Stock Analyst at Scotiabank
(3.13)
# 1,248
Out of 4,996 analysts
300
Total ratings
46.34%
Success rate
0.52%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $18.36 | +335.73% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.99 | +352.26% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $16.05 | -12.77% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.79 | +570.39% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $18.86 | +191.62% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $58.99 | -6.76% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.40 | +341.18% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $59.59 | -16.09% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $5.54 | +170.76% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $14.16 | +20.06% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $42.95 | +62.98% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $13.15 | +280.23% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.80 | +206.12% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $31.62 | +73.94% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.89 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $55.61 | +187.72% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.98 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $220.61 | +8.79% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $23.76 | +89.39% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $179.71 | +19.64% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.77 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $78.56 | +97.30% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.17 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $724.54 | +22.15% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.99 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.23 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.86 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.47 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $90.50 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.86 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.72 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.00 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.02 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $563.90 | +64.04% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.08 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.26 | +1,893.87% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.58 | +216.46% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $3.48 | +618.39% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.64 | +219.69% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $17.57 | +184.58% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.07 | +367.29% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.33 | +2,612.48% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.15 | +78,488,272.09% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $289.69 | -10.94% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $18.34 | -18.21% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.21 | +4,032.23% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.45 | +1,279.31% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.04 | +539.30% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $18.36
Upside: +335.73%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.99
Upside: +352.26%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $16.05
Upside: -12.77%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.79
Upside: +570.39%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.86
Upside: +191.62%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $58.99
Upside: -6.76%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.40
Upside: +341.18%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $59.59
Upside: -16.09%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.54
Upside: +170.76%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $14.16
Upside: +20.06%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $42.95
Upside: +62.98%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $13.15
Upside: +280.23%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.80
Upside: +206.12%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $31.62
Upside: +73.94%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.89
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $55.61
Upside: +187.72%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.98
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $220.61
Upside: +8.79%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $23.76
Upside: +89.39%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $179.71
Upside: +19.64%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.77
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $78.56
Upside: +97.30%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.17
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $724.54
Upside: +22.15%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.99
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.23
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.86
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.47
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $90.50
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.86
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.72
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.00
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.02
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $563.90
Upside: +64.04%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.08
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.26
Upside: +1,893.87%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.58
Upside: +216.46%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $3.48
Upside: +618.39%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.64
Upside: +219.69%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $17.57
Upside: +184.58%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.07
Upside: +367.29%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.33
Upside: +2,612.48%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.15
Upside: +78,488,272.09%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $289.69
Upside: -10.94%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $18.34
Upside: -18.21%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.21
Upside: +4,032.23%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.45
Upside: +1,279.31%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.04
Upside: +539.30%